ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
UCB and Biogen Idec have formed a collaboration to develop and commercialize the UCB drug CDP323 for the treatment of relapsing-remitting multiple sclerosis. CDP323 is a small-molecule α4 integrin inhibitor expected to enter Phase II clinical trials next year. Under the deal, UCB will receive upfront and other payments in excess of $200 million. Biogen's main drug, Avonex, is an MS treatment.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter